Product Pathways - Growth Factors/Cytokines
Mouse Interleukin-10 (mIL-10) #5261
|5261LF||50 µg (Carrier Free)||---||In Stock||---|
|5261LC||50 µg (With Carrier)||---||In Stock||---|
|5261SC||10 µg (With Carrier)||---||In Stock||---|
|5261SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse IL-10 (mIL-10) Ser19 - Ser178 (Accession # NP_034678) was produced in E. coli at Cell Signaling Technology.
Recombinant mIL-10 does not have a Met on the amino terminus and has a calculated MW of 18,976. DTT-reduced and non-reduced protein migrate as 19 kDa polypeptides. The expected amino-terminal SRGQY of recombinant mIL-10 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-10. All lots are greater than 98% pure.
The bioactivity of recombinant mIL-10 was determined in a MC/9 cell proliferation assay. The ED50 of each lot is between 0.3-1.3 ng/ml.
The purity of recombinant mIL-10 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-10 and staining overnight with Coomassie Blue.
The proliferation of MC/9 cells treated with increasing concentrations of mIL-10 in the presence of 1 pg/ml mouse IL-4 (#5208) was assessed. After 72 hour treatment with mIL-10 cells, were incubated with a tetrazolium salt and the OD450-OD650 was determined.
Western blot analysis of extracts from MC/9 cells, untreated or treated with mIL-10 for 20 minutes, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) or Stat3 Antibody #9132 (lower).
Less than 0.01 ng endotoxin/1 μg mIL-10.
With carrier: A 0.22 μm filtered solution of 0.33 mg/ml mIL-10 in PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-10. Carrier free: A 0.22 μm filtered solution of 0.33 mg/ml mIL-10 in PBS, pH 7.2.
IL-10 is an anti-inflammatory cytokine that is produced by T cells, NK cells, and macrophages (1,2). IL-10 initiates signal transduction by binding to a cell surface receptor complex consisting of IL-10 RI and IL-10 RII (1). Binding of IL-10 leads to the activation of Jak1 and Tyk2, which phosphorylates Stat3 (1,3). The anti-inflammatory activity of IL-10 is due to its ability to block signaling through other cytokine receptors, notably IFNγ receptor, by upregulating expression of SOCS1 (1,3). In addition, IL-10 promotes T cell tolerance by inhibiting tyrosine phosphorylation of CD28 (4,5). IL-10 is an important negative regulator of the immune response, which allows for maintenance of pregnancy (1). In contrast, increased IL-10 levels contribute to persistent Leishmania major infections (6).
- Pestka, S. et al. (2004) Immunol Rev 202, 8-32.
- Akuffo, H. et al. (1999) Clin Exp Immunol 117, 529-34.
- O'Shea, J.J. and Murray, P.J. (2008) Immunity 28, 477-87.
- Akdis, C.A. and Blaser, K. (2001) Immunology 103, 131-6.
- Akdis, C.A. et al. (2000) FASEB J 14, 1666-8.
- Von Stebut, E. Eur J Dermatol 17, 115-22.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.